Atypical hemolytic uremic syndrome triggered by mRNA vaccination against SARS-CoV-2 : case report
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F22%3A00083477" target="_blank" >RIV/00023001:_____/22:00083477 - isvavai.cz</a>
Alternative codes found
RIV/00064165:_____/22:10449969 RIV/00216208:11110/22:10449969 RIV/00216208:11150/22:10449969
Result on the web
<a href="https://www.frontiersin.org/articles/10.3389/fimmu.2022.1001366/full" target="_blank" >https://www.frontiersin.org/articles/10.3389/fimmu.2022.1001366/full</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3389/fimmu.2022.1001366" target="_blank" >10.3389/fimmu.2022.1001366</a>
Alternative languages
Result language
angličtina
Original language name
Atypical hemolytic uremic syndrome triggered by mRNA vaccination against SARS-CoV-2 : case report
Original language description
Atypical hemolytic uremic syndrome (aHUS), also called complement-mediated hemolytic uremic syndrome (CM-HUS), is a rare disease caused by dysregulation in the alternative complement activation pathway. It is a life-threatening condition causing ischemia of a number of organs, and it typically causes acute kidney injury. This disorder may be triggered by various factors including viral or bacterial infections, pregnancy, surgery, and injuries. In about 60% of cases, the genetic origin of the disease can be identified-commonly mutations affecting complementary factor H and MCP protein. Eculizumab, a monoclonal antibody to the C5 component of the complement, represents the current effective treatment.We describe a case of a young woman with a previous history of polyvalent allergies, who developed atypical hemolytic uremic syndrome after vaccination with mRNA vaccine against SARS-CoV-2. The disease manifested by scleral bleeding, acute renal insufficiency, anemia, and thrombocytopenia. The patient was treated with plasma exchanges without sufficient effect; remission occurred only after starting treatment with eculizumab. Genetic examination showed that the patient is a carrier of multiple inherited risk factors (a rare pathogenic variant in CFH, MCPggaac haplotype of the CD46 gene, and the risk haplotype CFH H3). The patient is currently in hematological remission with persistent mild renal insufficiency, continuing treatment with eculizumab/ravulizumab. By this case report, we meant to point out the need for careful monitoring of people after vaccination, as it may trigger immune-mediated diseases, especially in those with predisposing factors.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30217 - Urology and nephrology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Frontiers in immunology [online]
ISSN
1664-3224
e-ISSN
1664-3224
Volume of the periodical
13
Issue of the periodical within the volume
September 28
Country of publishing house
CH - SWITZERLAND
Number of pages
9
Pages from-to
"art. no. 1001366"
UT code for WoS article
000872783800001
EID of the result in the Scopus database
2-s2.0-85140125547